During the corresponding time, Optinose Inc recorded a revenue increase by 83.27 % year on year, sequentially revenue grew by 21.64 %. While revenue at the Optinose Inc 's corporate clients
Optinose Inc's Comment on Sales, Marketing and Customers
The company targets approximately 5,600 to 7,000 ENT specialists, allergists, and specialty-like primary care physicians through a sales force of 75 territory managers, utilizing both in-person and digital/non-personal promotion. Educational materials about XHANCE are provided, with potential plans to expand the sales force and territories. The company is also considering direct-to-consumer advertising to increase prescriptions. The XHANCE Co-Pay Savings Program offers co-pay assistance to eligible commercially insured patients, potentially reducing out-of-pocket costs to zero. Approximately 70% of insured lives are covered by plans that include XHANCE, although many plans require prior authorizations or step-edits, which can limit patient access. The company negotiates with payors to balance access, affordability, coverage, utilization management, and rebate levels. Historically, XHANCE was sold primarily to PPN partners, providing patients with preferred pharmacy networks offering services such as mail delivery and insurance verification. In January 2024, a patient support program (HUB) was launched to assist patients with payor restrictions and affordability solutions.
Optinose Announces Positive Results of XHANCE Clinical Trial in the Journal of Allergy and Clinical Immunology: In Practice Optinose, a pharmaceutical company specializing in innovative therapies for chronic sinusitis, has recently published the findings of the ReOpen Phase 3 Clinical Trial Program in the prestigious Journal of Allergy and Clinical Immunology: In Practice. These trials evaluated the efficacy and safety of XHANCE, a novel nasal spray, in the treatment of chronic sinusitis.Chronic sinusitis, also known as chronic rhinosinusitis, is a prevalent condition affecting millions of individuals worldwide. It is characterized by long-term inflammation of the sinuses, leading to symptoms such as facial ...
Optinose Inc’s Comment on Sales, Marketing and Customers
The company targets approximately 5,600 to 7,000 ENT specialists, allergists, and specialty-like primary care physicians through a sales force of 75 territory managers, utilizing both in-person and digital/non-personal promotion. Educational materials about XHANCE are provided, with potential plans to expand the sales force and territories. The company is also considering direct-to-consumer advertising to increase prescriptions. The XHANCE Co-Pay Savings Program offers co-pay assistance to eligible commercially insured patients, potentially reducing out-of-pocket costs to zero. Approximately 70% of insured lives are covered by plans that include XHANCE, although many plans require prior authorizations or step-edits, which can limit patient access. The company negotiates with payors to balance access, affordability, coverage, utilization management, and rebate levels. Historically, XHANCE was sold primarily to PPN partners, providing patients with preferred pharmacy networks offering services such as mail delivery and insurance verification. In January 2024, a patient support program (HUB) was launched to assist patients with payor restrictions and affordability solutions.
Sources:
Optinose Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Optinose Inc’s corporate clients.
For your research, we’ve provided 9 tables on Optinose Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
67.88 %